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Abstract  
Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are two major forms 
of leukemia developed from myeloid cells (MCs). To understand why AML and CML occur 
in children, we analyzed the causes and the mechanism of cell transformation of a MC. I. 
DNA changes in cells are generated as consequences of cell injuries and DNA injuries. For 
the MCs and hematopoietic stem cells (HSCs) in marrow cavity, repeated bone-remodeling 
during bone-growth and bone-repair may be a source of cell injuries. II. As a type of blood 
cell, a MC may have higher survivability from DNA changes and require obtaining fewer 
cancerous properties for cell transformation than a tissue cell. III. Point DNA mutations 
(PDMs) and chromosome changes (CCs) are the two major types of DNA changes. CCs have 
three subtypes by their effects on a cell: great effect CCs (GECCs), mild-effect CCs (MECCs), 
and intermediate-effect CCs (IECCs). A GECC affects one or more genes and can alone 
trigger cell transformation. PDMs/MECCs are mostly mild and can accumulate in cells. Some 
of the PDMs/MECCs contribute to cell transformation. An IECC affects one or more genes 
and participates in cell transformation. IV. Based on II and III, we hypothesize that a MC 
may have two pathways on transformation: a slow and an accelerated. Slow pathway is driven 
by accumulation of PDMs/MECCs through many generations of cells. Accelerated pathway is 
driven by accumulation of PDMs/MECCs/IECC(s) through a few generations of cells. In both 
pathways, long-term accumulation of DNA changes occurs in regenerable HSCs. A 
transformation via slow pathway occurs at old age; whereas that via accelerated pathway 
occurs at any age.  Thus, CML and pediatric AML may develop via accelerated pathway, and 
adult AML may develop via slow or accelerated pathway. In conclusion, pediatric AML and 
CML may develop as a result of cell transformation of a MC via accelerated pathway; and the 
repeated bone-remodeling during bone-growth may be a trigger for the cell transformation of 
a MC in a child.  
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I. Introduction 
Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are two major forms 
of leukemia arising from myeloid cells (MCs) in marrow. “MCs” include all the cells of 
myeloid linage at any developing stages.  AML and CML occur mostly in adults but also in 
children. Myelodysplastic syndrome (MDS) is a type of pre-leukemia that occurs mainly in 
old people. In updated WHO classification of AML and MDS in 2016, some subtypes of 
AML are renamed by their specific DNA changes, for example, “AML with t(6;9)” and 
“AML with t(8;21)” (Arber, 2016). The novel classification of AML is important in clinic for 
making a more precise diagnosis and prognosis of an AML. Nevertheless, in this paper, we 
discuss AML by using the FAB classification of AML subtypes (M0-M7). The classic name 
of an AML subtype gives information of the pathology and the cell of origin of an AML. On 
the causing factors for leukemia, we have recently proposed a hypothesis: repeated bone-
remodeling during bone-growth may be a source of cell injuries of the hematopoietic cells 
(HCs) in marrow (Wang-Michelitsch, 2018a). HCs include hematopoietic stem cells (HSCs), 
MCs, and the lymphoid cells (LCs) in marrow. We discuss in this paper the developing 
mechanisms of AML and CML by this hypothesis. Our discussion is driven by the following 
questions:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We aim to show by our discussion that: pediatric AML and CML may develop as a result of 
cell transformation of a MC via accelerated pathway; and the repeated bone-remodeling 
What is the cause for cell injuries of 
myeloid cells (MCs) in marrow? 
 
 
Why can a MC be transformed 
more rapidly than a tissue cell? 
 
 Is it possible that repeated 
bone-remodeling is a source 
of cell injuries of MCs? 
Why do AML and CML occur in children? 
 
Is a MC different 
from a tissue cell on 
transformation? 
 
What a type of DNA changes 
is associated with the rapider 
transformation of a MC? 
 
 
Is the rapider 
transformation of MC 
driven by a 
chromosome change? 
 
Does a MC have 
higher tolerance to 
DNA changes than a 
tissue cell? 
 
Does a MC require obtaining 
fewer cancerous properties 
for transformation than a 
tissue cell?  
 
 Email : thomasjicun@gmail.com  5 
 
during bone-growth may be related to the cell transformation of a MC in a child. We use the 
following abbreviations in this paper: 
AML: acute myeloid leukemia 
ALL: acute lymphoblastic leukemia 
BL: Burkitt lymphoma  
CML: chronic myeloid leukemia  
CLL: chronic lymphocytic leukemia 
DLBCL: diffuse large B-cell lymphoma 
DSB: double-strand break of DNA 
GMP: granulocyte-monocyte progenitor
GECC: great-effect chromosome change 
HC: hematopoietic cell 
HSC: hematopoietic stem cells  
IECC: intermediate-effect chromosome change 
JMML: Juvenile myelomonocytic leukemia 
LC: lymphoid cell 
LCCI: loss of cell-contact inhibition 
LPC: lymphoid progenitor cell 
MC: myeloid cell 
MDS: myelodysplastic syndrome 
MECC: mild-effect chromosomal change 
MEP: megakaryocyte-erythrocyte progenitor  
MPC: myeloid progenitor cell 
MPN: myeloid proliferative neoplasm 
PDM: point DNA mutation  
SIM: stimulator-independent mitosis
 
II. Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) affect 
both adults and children  
AML and CML affect both adults and children, but MDS affects mainly the people older than 
age 60 (Figure 1). AML can occur in infants, and has a small peak before age 2. 10% of CML 
patients are children and adolescents; however CML occurs rarely in children under age 4. 
Pediatric AMLs can be different from adult cases by disease presentation, pathology, and 
prognosis. Leukemia patients at different ages need to be given different treatments, thus they 
are regrouped often by age: infants (age 0-2), children (age 3-14), adolescents (age 15-19), 
young adults (age 20-39), and adults (age > 39). Pediatric patients are the patients that are 
younger than age 15 (Kent, 2009). AML and MDS have much higher incidences than CML. 
In USA, the incidences of AML, CML and MDS in 2013 are respectively 12950, 5980, and 
14100.  All these three forms of leukemia have higher incidences in males than in females. 
 
 
 
 
 
 
 
 
 
Figure 1. Age-specific incidences of AML, CML and MDS (a schematic graph) 
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AML (blue line) and CML (green line) occur mostly in adults but also in children. AML can occur in infants, and 
has a small peak before age 2. CML occurs rarely before age 4. MDS occurs mainly in old people (black line). 
AML and MDS have much higher incidences than CML. 
 
2.1   AML occurs at all ages but mostly in adults 
AML is a form of blood cancer that exhibits as abnormal cloning and differentiation of 
myeloid blast cells in marrow. AMLs account for 80% of adult leukemia cases and 15% of 
pediatric cases. AML has increasing incidence with age (Figure 1). However, AML has a 
small peak before age 2 (Pérez-Saldivar, 2011). It is not clear yet what is the main causing 
factor for AML. Possible causes include genetic disorders and exposures to ionizing radiation 
or organic solvents. For infant AML (IAML), exposures to radiation/chemicals or smoking of 
the mother during pregnancy may be a cause in some cases. The infants with some hereditary 
conditions, such as Down syndrome, Fanconi anemia, Diamond-Blackfan syndrome, and Li-
Fraumeni syndrome, have high risk of IAML development (Saida, 2017).  
2.1.1 Different subtypes of AML occur at different ages  
By pathology, AML is classified into M0-M7 eight subtypes. Diagnosis of a subtype of AML 
is based on the characteristics of leukemic cells on morphology, immunophenotype, and 
cytogentic changes (Saultz, 2016). The names of AML subtypes are listed here: M0: 
Undifferentiated acute myeloblastic leukemia; M1: Acute myeloblastic leukemia with 
minimal maturation; M2: Acute myeloblastic leukemia with maturation; M3: Acute 
promyelocytic leukemia (APL); M4: Acute myelomonocytic leukemia; M4eos: Acute 
myelomonocytic leukemia with eosinophilia; M5: Acute monocytic leukemia; M6: Acute 
erythroid leukemia; and M7: Acute megakaryoblastic leukemia. Different subtypes of AML 
have different incidence rates in population and have different age-distributions. M0, M1 and 
M2 are all myeloblastic leukemia and together represent 45% of AMLs. The incidence rates 
of M3, M4/M4eos, and M5 are respectively 10%, 25%, and 10%. M6 and M7 are rare 
(Santos, 2009; Masetti, 2015).  
M0 occurs mostly in infants and older adults (Venditti, 1997). M1 and M2 are the most 
common subtypes of AML in children and adults, but they are rare in infants (Table 1). M3 
occurs mostly at age 35-40. 50% of IAMLs are M4 and M5, and 20% are M7 (Masetti, 2015). 
M6 occurs mostly in people older than age 60 (Santos, 2009). M7 is the most common 
subtype of AML in Down’s children. A child with Down syndrome may have 16-fold higher 
risk than other children on developing AML. Familiar AMLs occur mostly before age 3. In 
general, pediatric AMLs have better prognosis than adult cases after treatment. However, 
most IAMLs are chemotherapy-resistant. The 5-year overall survival rates (OS) in infants, 
children, and adults (age >15) are respectively 10%-30%, 50%, and 30%-40% (Master, 2016). 
Among all subtypes of AML, APL (M3) has the best prognosis (Kansal, 2016).  
2.1.2   Different subtypes of AML have different forms of recurrent DNA changes  
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More than 300 forms of chromosome changes (CCs) and molecular mutations have been 
identified in AML cells. CCs have higher occurrences in pediatric AMLs: in 70%-85% of 
pediatric AMLs whereas in 50% of adult cases (Kumar, 2011). Different subtypes of AML 
often have different recurrent forms of CCs in tumor cells (Kansal, 2016). The most frequent 
forms of CCs in each subtype are respectively: M0: complex karyotypes; M1 : t(9;22), (+8), 
(-5), (-5q), and abn(3q); M2: t(8; 21), t(3;21), and t(6;9); M3: t(15;17) and t(11;17); M4 and 
M4eo: inv (16); M5: t(4;11), t(9; 11), and t(11;19); M7: t(1;22) and (+21) (Table 1). Some 
forms of CCs seem to be age-specific. For example, t(1;22), t(5;11), t(7;12), and complex 
karyotypes are forms of CCs mainly seen in infants. 5%-30% of IAMLs have t(1;22) and 14% 
have complex karyotypes.  t(1;22) is seen only in new babies whereas complex karyotypes are 
observed in infants older than 6 months. MLL rearrangements are forms of CCs often seen in 
IAMLs (Balgobind, 2011). They include t(4;11) (MLL/AF4), t(9;11) (MLL/AF9), and 
t(11;19). 35%-50% of IAMLs have t(4;11). Differently, t(8;21) is found mainly in older 
children and adults. Forms such as (-5), (-5q), and abn (3q) are seen only in adults.  
Gene mutations are also common in AMLs, and the most frequent ones are mutations on 
NPM1 (in 40%-60% of AMLs), FLT-ITD (30%), and CEBPA (15%) (Table 1) (Kumar, 2011; 
Nardi, 2016). Familiar AMLs have often mutations on RUNX1, CEBPA, and MLL (Stieglitz, 
2013).  Among all these forms of CCs and gene mutations, some are related to disease 
prognosis. The forms associated with good prognosis of AML include t(15;17),  t(11;17), 
t(8;21) and t(3;21), inv(16), and CEBPA mutations (Kumar, 2011). Those associated with 
intermediate prognosis of AML include t(9; 11), (+8), (-y), and mutations of NPM1 and FLT-
ITD. Those associated with poor prognosis are t(6;9),  t(9;22), (-5), (-7), inv (3) (GATA2 
insufficiency), abn(3q), complex karyotypes, and mutations of MLL, C-kit, TP53, and RUNX1 
(Foucar, 2015).  
 
Table 1. Different subtypes of AML have different recurrent DNA changes  
 Infants (< age 2) Children (age 3-14) Adults (> age 15) 
Main subtypes of AML M0, M4/M4eo, M5, and M7 M1, M2, M4, and M5 M1, M2, M3, and M6 
Chromosome changes  M0: complex karyotypes               
M4: inv (16)                                      
M5: t(4;11), t(9;11),  and 
t(11;19)                                      
M7: t(1;22) and (+21) 
M1: t(9;22)  and ( +8)                            
M2: t(8;21), t(3;21), and t(6;9)                                              
M4: inv (16)                               
M5: t(4;11), t(9;11), and 
t(11;19)  
M1: t(9;22), (+8), (-5), (-5q), and 
abn(3q)                        
M2: t(8;21), t(3;21), and t(6;9)                                                                   
M3: t(15;17) and  t(11;17)          
Gene mutations RUNX1 and MLL in familiar AML NPM1,FLT-ITD,and CEBPA NPM1, FLT-ITD, and CEBPA  
5-year survival rates  10%-30% 50% 30%-40% 
 
 
2.2   CML occurs in both children and adults 
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CML is an indolent form of blood cancer and it exhibits as over-production of all types of 
blood cells in myeloid lineage (Sarwar, 2015). CML occurs in both children and adults 
(Figure 1). 10% of CML patients are children and adolescents (Höglund, 2015). However, 
CML occurs rarely in young children (< age 4) (Homans, 1984).  About 30% of CML patients 
develop AML after 3-4 years of CML. Progression of CML into AML has three phases: 
chronic phase (CML-CP), accelerating phase (CML-AP), and transforming phase (CML-TP, 
called also blast crisis). 85% of CMLs are diagnosed at chronic phase. However, pediatric 
CMLs are often diagnosed at accelerating phase or transforming phase. Pediatric CML seems 
to be more aggressive than adult CML.  
2.2.1   Ph translocation is an essential DNA change in CML development  
Philadelphia (Ph) translocation (t(9;22)) is a characteristic DNA change in CML. 95% of 
CMLs have Ph translocation in leukemia cells. Ph translocation results in generation of fusion 
gene of BCR-ABL1. ABL1 is a tyrosine kinase that mediates the signal transduction of some 
stimulators that can activate cell proliferation.  Fusion of ABL1 gene with BCR gene results in 
permanent activation of ABL1 tyrosine kinase and unlimited cell proliferation of MCs 
(Bennour, 2015). Thus, inhibiting the activity of tyrosine kinase by specific inhibitors is a way 
to slow down the cell proliferation of MCs in CML. Clinical studies have shown that tyrosine 
kinase inhibitors (TKIs) including imatinib are effective drugs on controlling CML. CML-CP 
is curable by TKIs (Jain, 2016).  
However, Ph translocation is not specific for CML. Ph translocation is also found in 10%-
20% of cases of acute lymphoblastic leukemia (ALL). In these ALLs, Ph translocation 
contributes to the cell transformation of lymphoblast. Ph translocation is the main form of CC 
in CML at chronic phase. However, secondary DNA changes can be generated during the 
progression of CML. Some of the secondary DNA changes may lead to blast crisis of CML. 
These secondary DNA changes include t(8;21), second Ph translocation, isochromosome 17q, 
and (+19) (Bozkurt, 2013).  
2.2.2   CML is a form of myeloid proliferative neoplasm (MPN) 
CML is a proliferative disease, as a type of MPN. Other types of MPN include polycythemia 
vera (PV), essential thrombocytosis (ET), primary myelofibrosis (PMF), chronic eosinophilic 
leukemia (CEL), and chronic neutrophilic leukemia (CNL) (Clara, 2016). Each type of MPN 
is a result of cloning proliferation of a MC. CML occurs in both children and adults, but other 
types of MPN develop mainly in old people. In addition, CML affects all the MCs in five 
myeloid lineages, but each of PV, ET, CEL, and CNL affects only one of the five lineages of 
MCs. These types of MPN do not have Ph translocation in leukemia cells. 95% of PV/ET and 
50% of PMF have JAK2 V67F mutations or exon 12 mutations. These mutations lead to 
permanent activation of JAK 2 kinase in cells (Bose, 2017). JAK2 inhibitors such as 
ruxolitinib have been developed for treating MPNs. 
2. 3   Myelodysplastic syndrome (MDS) occurs mainly in old people 
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MDS is a group of neoplasms characterized by peripheral cytopenia as a result of ineffective 
hematopoiesis in marrow. MDS is a type of pre-leukemia because MDS becomes AML when 
the blast count in marrow increases to 20%. In updated WHO classification of MDS in 2016, 
five major subtypes of MDS are renamed (Arber, 2016). More than 40 forms of gene 
mutations have been identified in MDS; however, 80% of MDS patients have only one or two 
of these mutations (Harada, 2015). Frequent mutations in MDS include mutations of SF3B1, 
EZH2, TET2, SRSF2, ASXL1, RUNX1, and TP53. Notably, most of these mutations can be 
found also in healthy old people. CCs have low recurrences in MDS (Pellagatti, 2015).  Apart 
from del(5q), frequent forms of CCs in MDS include del(7q), del(20q), (-5), -Y, (+8), and (-7) 
(Haase, 2008). Some forms of CCs, including (+8), complex karyotype, and abn(7), are 
associated with poor prognosis of MDS.  
2.4  Juvenile myelomonocytic leukemia (JMML) is a type of MDS/MPN  
JMML is an aggressive form of hematopoietic disorder in infancy characterized by excessive 
production of monocytes and granulocytes (Toren, 1991; Sethi, 2013). In new WHO 
classification, JMML is entitled as a type of MDS/MPN (Clara, 2016; Arber, 2016). In JMML, 
over-production of monocytes and granulocytes leads to extensive infusion of monocytes in 
organs and in skin. JMML does not have Ph translocation in leukemia cells, and this makes 
JMML distinguishable from pediatric CML. JMML affects more often boys than girls. JMML 
is not sensitive to treatment, thus has poor prognosis. Over 20% of JMMLs have abnormality 
on chromosome 7, such as (-7), (+7), t(7;11), and t(7;20) (de Vries, 2010). The JMML in 
these cases is also called chromatide-7 syndrome. 30% of JMML children have genetic 
defects, such as Down syndrome, Shwachman-diamond syndrome, Fanconi anemia, and 
Kostmann syndrome (Luna-Fineman, 1999).  These genetic disorders have all abnormalities 
on chromosome 7. 90% of JMML patients carry gene mutations of proteins that are related to 
RAS/MAPK pathway, such as PTPN11, KRAS, NRAS, CBL, and NF1. The frequencies of 
mutations of PTPN11, NRAS, and NF1 in JMML are respectively 30%, 25%, and 15% 
(Locatelli, 2015).  
III. Development of myeloid cells (MCs) in bone marrow  
AML and CML are both a leukemia resulting from cell transformation of a MC. To 
understand how a MC is transformed, we firstly make a brief review on the developing 
process of MCs and the characteristics of MCs. In humans, after birth, all of our blood cells 
including MCs and lymphoid cells (LCs) are produced by the HSCs in marrow through 
hematopoiesis.  Hematopoiesis has in general four steps: A. a HSC produces a progenitor cell; 
B. a progenitor cell then proliferates rapidly to produce a large number of blast cells in 
different lineages; C. a blast cell then proliferates and differentiates into different types of 
pro-cytes (immature cells); and D. a pro-cyte then divides for several times to develop into 
mature cells (Figure 2). In the present paper, “hematopoietic cell" (HC) is the general name 
for all the blood forming cells in marrow, including HSCs, MCs, and LCs. Among all the 
nucleated non-erythroid HCs in marrow, 0.001% are HSCs, 2%-4% are blast cells, 20%-30% 
are pro-cytes, and more than 60% are mature cells. 
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Figure 2. Development of myeloid cells in marrow  
HSCs are the stem cells for all types of blood cells. For hematopoiesis, a HSC needs to produce a progenitor cell: 
myeloid progenitor cell (MPC) or lymphoid progenitor cell (LPC). A MPC differentiates firstly into three types of 
progenitor cells: megakaryocyte-erythrocyte progenitor (MEP), granulocyte-monocyte progenitor (GMP), and 
mast-cell progenitor.  A MEP will differentiate into two types of blast cells: megakaryoblasts and erythroblasts, 
which will differentiate further respectively into pro-megakaryocytes and pro-erythocytes. A GMP will 
differentiate into two types of blast cells: monoblasts and myeloblasts. A myeloblast will differentiate further 
into three types of pro-myelocytes: neutrophilic, basophilic, and eosinophilic, respectively. A monoblast will 
differentiate uniquely into pro-monocytes. Pro-cytes are also proliferative but uni-potent. Each pro-cyte will 
differentiate into a number of mature cells of the same type. Myeloid cells (MCs) include all the cells in myeloid 
lineage, and lymphoid cells (LCs) include all the cells in lymphoid lineage. Hematopoietic cells (HCs) include all 
the HSCs, MCs and LCs in marrow.   
 
3.1   Ancestors of MCs: hematopoietic stem cells (HSCs) 
HSCs are the ancestors for all HCs and all blood cells. HSCs are regenerable for our whole 
lifetime. Through symmetrical cell division, a HSC renews itself by producing two daughter 
HSCs. By asymmetrical cell division, a HSC produces two different cells:  a new HSC and a 
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progenitor cell: myeloid progenitor cell (MPC) or lymphoid progenitor cell (LPC) (Figure 2). 
MPCs are the ancestors for all the cells of myeloid lineage, LPCs are the ancestors for all the 
cells of lymphoid lineage. In a normal marrow, 75% of nucleated cells are of myeloid lineage 
and 20% are of lymphoid lineage. Since HSCs are the unique source of new blood cells, an 
abnormality on the number or on the functionality of HSCs may lead to a severe disease. For 
example, aplastic anemia may occur if HSCs have defects on regeneration. If a HSC is 
transformed by acquired DNA changes, clonal hematopoiesis or failure of hematopoiesis may 
occur. It is reported that clonal hematopoiesis occurs in 20% of people older than age 90 
(Shlush, 2015).  Some MDSs may develop from clonal hematopoiesis. 
3.2   Developing MCs: including progenitor cells, myeloblasts, and pro-cytes 
Progenitor cells, myeloblasts, and pro-cytes are precursors of mature MCs. Progenitor cells 
and blast cells are oligo-potent, whereas pro-cytes are uni-potent (Arai, 2016). A progenitor 
cell proliferates and differentiates into different types of blast cells, and a blast cell will 
proliferate and differentiate into one or more types of pro-cytes. For example, a MPC can 
firstly differentiate into three types of progenitor cells (also blast cells): megakaryocyte-
erythrocyte progenitor (MEP), granulocyte-monocyte progenitor (GMP), and mast-cell 
progenitor. A MEP will differentiate into two types of blast cells: megakaryoblasts and 
erythroblasts, which will differentiate further respectively into pro-megakaryocytes and pro-
erythocytes. A GMP will differentiate into two types of blast cells: monoblasts and 
myeloblasts. A myeloblast will differentiate further into three types of pro-myelocytes: 
neutrophilic, basophilic, and eosinophilic, respectively (Figure 2). Differently, a monoblast 
will differentiate uniquely into pro-monocytes. Pro-cytes are also proliferative but uni-potent. 
Each pro-cyte will differentiate into a number of mature cells of the same type. In myeloid 
lineage, a pro-cyte develops into mature cells via three stages of differentiation: pro-cyte, cyte, 
and meta-cyte. For example, maturation of neutrophilic granulocytes needs to pass three 
developing stages: pro-myelocyte, myelocyte and mega-myelocyte.  
Progenitor cells, blast cells, and pro-cytes are all developing HCs, which are proliferative and 
immature on cell functions. Blast cells account for 2%-4% of nucleated HCs in marrow. The 
number of pro-cytes should be much higher than that of blast cells, because a blast cell needs 
to divide at least one time to develop into pro-cytes.  Thus, pro-cytes may represent the largest 
part of developing HCs in marrow. Although not fully developed, pro-cytes are more mature 
on cell functions than blast cells. Being large in number and proliferating constantly, 
developing HCs may have high risk to be injured during DNA synthesis and cell division by 
damaging factors. In another word, developing HCs have higher risk of DNA injuries and 
DNA changes than mature cells.  
3.3   Mature MCs: including granulocytes, monocytes, red cells, and megakaryocytes  
A pro-cyte will divide for several times to develop into mature cells. Except T cells, all types 
of blood cells are fully developed in marrow. Mature MCs have several sub-lineages, 
including granulocytes (neutrophils, basophils, and eosinophils), monocytes, erythrocytes (red 
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cells), and megakaryocytes (platelets) (Figure 2). Being mature on cell functions and non-
proliferative, a mature MC may have lower risk of DNA injuries and DNA changes than a 
developing MC. Monocytes and granulocytes are the main cells for innate immunity. 
Monocytes can derive into macrophages, osteoclasts, and dendritic cells.  The functions of 
monocytes are phagocytosis, cytokine production, and antigen-presentation. A monocyte is a 
large cell with big smooth nucleus and large cytoplasm. This indicates that a monocyte 
produces a large number of intracellular proteins. A granulocyte is a middle-sized cell, but 
much bigger than a naïve lymphocyte by its large cytoplasm. A granulocyte produces a great 
deal of granule proteins in cytoplasm. These proteins are important for the function of a 
neutrophil: swallowing and digesting bacteria and fungi in cytoplasm.  
IV. A potential source of cell injuries of hematopoietic cells (HCs) in marrow: the 
repeated bone-remodeling during bone-growth and bone-repair 
DNA changes are the driver for cell transformation and for cancer development. However, 
DNA changes are generated in a cell as consequences of cell injuries and DNA injuries. So far, 
the main cause for cell injuries of MCs associated with leukemia development is unknown.  
Some environmental factors such as exposures to radiation or toxic chemicals may be related 
to leukemia development. However, the high incidence of AML in young children cannot be 
explained completely by environmental factors. After analyzing the occurring age of ALLs, 
we have hypothesized that repeated bone-remodeling during bone-growth may be a source of 
cell injuries of HCs and a trigger for ALL development in children (Wang-Michelitsch, 
2018a).   
ALL occurs mostly at age 0-20 when the bones are growing. The incidence of ALL after age 
25 is very low. This phenomenon suggests that bone-growth may be related to ALL 
development. In humans, hematopoiesis takes place mainly in marrow cavities and the spongy 
part of bones. Marrow cavity and spongy bone are developed and enlarged with the growth of 
a bone. Bone-growth is a result of repeated modeling-remodeling of bone tissues (Rockville, 
2004).  Bone-remodeling is a process of digestion of the bone tissues exposed to marrow 
cavity by osteoclasts. Osteoclasts digest bone-matrix by secreting acid substances and 
proteinases. It is quite possible that these digestive substances and the bone debris produced 
during bone-remodeling injure occasionally the HCs in marrow cavity. Naturally, the risk of a 
HC to be injured by bone-remodeling is quite low. However, long-term (25 years) repetition 
of bone modeling-remodeling for bone-growth can highly increase this risk. 
In addition, young children have high incidence of bone fractures because of their fragilities 
on muscles and bones. Bone injuries may disturb bone-growth and increase the frequency of 
bone-remodeling. Thus, in a child, bone injuries (external) increase the risk of cell injuries of 
HCs by bone-remodeling during bone-growth (internal). In fact, bone-remodeling occurs also 
during bone-repair and bone adaptation. Thus HCs can be affected by bone-remodeling at all 
ages. Bone-remodeling may be a causing factor not only for pediatric leukemia but also for 
adult leukemia.  
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Cell injuries by internal damage may occur also to other cells including tissues during body 
development and during inflammations. DNA changes can be also generated in some injured 
tissue cells. However, for a tissue cell, cell transformation needs a long time as a co-effect of 
external and internal factors. Differently, a MC can be transformed more rapidly than a tissue 
cell as that seen in AML and CML. Thus, the effect of internal damage on a MC can be 
recognized. We will discuss in next parts why a MC can be transformed more rapidly than a 
tissue cell. 
V. Generation and accumulation of DNA changes in HCs is a result of repeated 
cell injuries and repeated cell proliferation  
There are two major types of DNA changes:  point DNA mutation (PDM) and chromosome 
change (CC). PDM appears as alteration, deletion, or insertion of one or two bases in a DNA. 
PDM is called also gene mutation and molecular mutation. CC is called also cytogenetic 
change and abnormal karyotype. A CC can be a numerical CC (NCC) or a structural CC 
(SCC). A NCC exhibits as loss or gain of one or more chromosomes. For example, (-7), (+7),   
hyperdiploid, and aneuploid are all forms of NCCs. A SCC exhibits as rearrangement of part 
of a chromosome, such as translocation (t), deletion (del), gain (+), inversion (inv), and 
amplification (amp) of part of a chromosome.  
Different types of DNA changes are generated in a cell by different mechanisms. Studies 
show that a PDM is generated as a result of Misrepair of DNA on a double-strand DNA break 
(DSB) (Rothkamm, 2002; Natarajan, 1993; Bishay, 2001). Similarly, generation of SCC is 
also a result of Misrepair of DNA.  A SCC can be generated when a cell has multiple DSBs 
(Wang-Michelitsch, 2018a). Differently, generation of NCC is rather a consequence of 
dysfunction of cell division promoted by damage.  In our view, a PDM/SCC is made for 
repair of DNA for preventing cell death, thus it is not really a mistake. Differently, a NCC is 
not generated for “repair”; thus survival of a cell with a NCC is a real mistake. Unfortunately, 
a NCC can affect multiple genes and cause cell transformation rapidly.  
Normally, a somatic cell has quite low opportunity to survive from a DSB by Misrepair of 
DNA. Thus, DNA mutations cannot accumulate in “the same” cell, but can only accumulate 
in its offspring cells (Wang-Michelitsch, 2015). Cell injuries are the triggers for generation of 
DNA changes. Cell proliferation enables the accumulation of DNA changes generated in 
different generations of offspring cells. Thus, accumulation of DNA changes in cells is a 
result of repeated cell injuries and repeated cell proliferation. For example, in bone marrow, 
repeated cell injuries of HCs may trigger generation of DNA changes in some HCs. 
Regeneration of HSCs and proliferation of HCs enable the DNA changes to accumulate in 
these cells. However, long-term accumulation of DNA changes (longer than months) can 
occur only in HSCs. Namely, only the DNA changes that are generated or inherited in HSCs 
can accumulate for a long time. But all the offspring cells of a HSC, including MCs, LCs, and 
mature blood cells, can inherit the DNA changes accumulated in the HSC. For example, a MC 
can have all the DNA changes of its precursor HSCs and other precursor cells (Wang-
Michelitsch, 2018a).  
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VI. Different types of DNA changes have different effects on a cell  
DNA changes are the driver for cell transformation; however, not all the DNA changes 
contribute to cell transformation. Big CCs may cause cell death, but silent PDMs have no 
effect on a cell. CCs are rare in cancers developed from tissue cells, but not rare in leukemia 
and lymphoma. This phenomenon indicates that a tissue cell can be transformed mainly by 
PDMs (gene mutations), but a blood cell and a HC can be transformed not only by PDMs but 
also possibly by CCs.  
6.1   Effect of a point DNA mutation (PDM) on a cell 
A PDM can affect at most “one” gene. Since most regions of a DNA (in one chromosome) are 
non-coding for proteins, most PDMs are silent in a cell. However, if a PDM occurs in the 
coding region of a gene and affects expression of the gene, the PDM is not silent. There may 
be two situations: A. if the gene is essential for cell survival and it is expressed constitutively, 
production of non-functional proteins or failure/reduction of gene expression can make the 
cell die; and B. if the gene is expressed only when there is an inducer, failure of gene 
expression does not necessarily cause cell death. In situation A, the PDM is fatal, but in 
situation B, the PDM is mild. Hence, most PDMs are silent or mild, by which they can 
“survive” and accumulate in cells. By accumulation, some mild PDMs may exhibit their 
“emergent effects” on a cell. If some of the PDMs make a cell able to proliferate 
independently, the cell is transformed. It is possible that some forms of PDMs do not affect 
directly cell functions but they may alter genome stability and accelerate generation of other 
DNA changes. These PDMs also contribute to cell transformation. 
6.2   Three types of chromosome changes (CCs) by their effects on a cell  
In AML, CCs can be found in 80% of pediatric cases but only 45% of adult cases. This 
phenomenon suggests that the rapider cell transformation of a MC in pediatric AML is related 
to CCs. In general, a CC has greater effect than a PDM on a cell, but different forms of CCs 
may have different effects. Thus it is essential to regroup CCs by their impacts on a cell. We 
classify CCs into three groups by their effects on a MC: great-effect CCs (GECCs), mild-
effect CCs (MECCs), and intermediate-effect CCs (IECCs) (Box 1).  
6.2.1   Great-effect CCs (GECCs) 
GECC is a type of CC that affects one or more genes and can alone drive cell transformation 
in “one step” (Box 1). For most types of cells, a GECC will cause cell death. However, for 
certain types of cells, a GECC may be not fatal, but rather be sufficient for driving cell 
transformation directly (Wang-Michelitsch, 2018b). The aneuploid in pediatric ALL and the 
t(8;14) in Burkitt lymphoma (BL) are  two examples of GECCs. ALL and BL have both a 
peak incidence in children, indicating that a lymphoblast and a centroblast have a risk to be 
transformed by a GECC. Differently, AML and CML do not have a peak incidence in 
children and other ages. This suggests that a MC cannot be transformed in “one-step” by a 
GECC. In another word, a MC cannot survive from a GECC. 
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Box 1. Different types of DNA changes have different effects on a cell 
 
 
 
 
 
 
 
 
6.2.2   Mild-effect CCs (MECCs)  
MECC is a type of CC that has silent or mild effect on a cell (Box 1). A MECC can be a CC 
occurred to a non-coding region of a DNA or to a coding part of a DNA but not affecting gene 
expression. Thus, a MECC has similar effect to a PDM on a cell. Among all the DNA 
changes in AML, those that are associated with low-risk prognosis, including t(15; 17), t(8; 
21), and inv(16), may be MECCs. Most of MECCs can accumulate in cells, and some of them 
may contribute to cell transformation. Since a NCC (numerical CC) can affect multiple genes, 
MECCs are often tiny SCCs (structural CCs). 
6.2.3   Intermediate-effect CCs (IECCs) 
IECC is a type of CC that affects one or more genes and contributes to cell transformation 
(Box 1). An IECC cannot alone cause cell death or cell transformation. A mature MC and a 
HSC may have low tolerance to an IECC. Thus, an IECC is generated more often in a 
developing MC, such as progenitor cell, blast cell, and pro-cyte. A cell may have increased 
risk of generation of IECC, when it has already other DNA changes. Some PDMs/MECCs 
may affect the chromosome stability in a cell and increase the sensitivity of a DNA to damage. 
Namely, the more PDMs/MECCs a cell has, the more risk has the cell on generation of IECC.  
Thus, IECCs have increasing occurrence in MCs with age of our body. IECCs may also 
accumulate in MCs, but this opportunity is low.  
The cell transformation driven by an IECC is a co-effect of the IECC and other 
PDMs/MECCs. One reason is that: generation of IECC is often related to early 
PDMs/MECCs in the cell. With stronger effect than a PDM/MECC, an IECC can accelerate 
cell transformation. An IECC drives cell transformation possibly by affecting an oncogene or 
a tumor suppressing gene. A good example of IECC is the Ph translocation (t(9;22)) in CML. 
Ph translocation contributes to the cell transformation of MC in CML by generating fusion 
gene of BCR-ABL1 and activating permanently ABL1 tyrosine kinase. CML occurs rarely in 
young children, but it has increasing incidence with age (Kang, 2016). This phenomenon 
Chromosomal 
change (CC)                       
Mild-effect CC                     
(MECC)                    
Point DNA mutation 
(PDM)                    Affecting at most one gene and possibly contributing to cell transformation                
Intermediate-effect CC:   affecting one or more genes and contributing to cell transformation                  
(IECC)                   
Great-effect CC: affecting one or more genes and alone driving cell transformation                      
(GECC)                     
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suggests that Ph translocation has increasing occurrence in MCs with age of an individual. 
IECCs might represent the cytogenetic abnormalities that are associated with intermediate- 
and high-risk prognosis of AML. These CCs include t(9; 11), (+8), (-y), t(6;9),  t(9;22), (-5), 
(-7), inv (3), and abn(3q). An IECC is a driver DNA change, thus it can be chosen to be a 
blocking target in targeted cancer treatment.  
VII. A MC may have higher survivability from DNA changes than a tissue cell 
Different forms of DNA changes have different effects on a cell; however, the same form of 
DNA change may have different effects on different types of cells. MCs at different 
developing stages may have also different tolerances to a DNA change.  In this and next parts, 
we discuss why a MC can be transformed more rapidly than a tissue cell. In our view, two 
factors make it possible that MC is transformed more rapidly. These two factors are: A. a MC 
may have higher tolerance to DNA changes than a tissue cell; and B. A MC may require 
obtaining fewer cancerous properties for transformation than a tissue cell.  
7.1   Higher tolerance of a MC to DNA changes than a tissue cell 
A blood cell is different from a tissue cell by surviving environment. Here, “blood cells” 
include all the mature blood cells and all the hematopoietic cells in bloodstream and in 
marrow. A tissue cell is anchor-dependent for survival, but a blood cell is anchor-independent. 
If a tissue cell fails to anchor to its neighbor cells or extracellular matrixes (ECMs), the cell 
will die through apoptosis (cell suicide).  For a tissue cell, cell adhesion molecules are 
essential for cell survival. Major types of adhesion molecules include cadherins, selectins, and 
integrins (Li, 2012).  If a DNA change affects production of one of these molecules in a tissue 
cell, the cell may die. A blood cell expresses also adhesion molecules. However, for a blood 
cell, the adhesion molecules are used for cell development and cell functions, but not used for 
anchoring to other cells/ECMs for survival. For example, a mature granulocyte can survive no 
matter whether it is in bone marrow, bloodstream, or tissue. Thus, cell adhesion molecules of 
a granulocyte are not essential for cell survival. Failure of expression of these molecules by 
DNA changes does not necessarily cause death of a granulocyte.  
In addition, at different developing stages, MCs express different CD molecules. For example, 
CD33 and CD34 are only expressed on developing MCs but not on mature MCs (Dutta, 2014).   
In contrast, molecules including CD17 and CD93 are only expressed on mature MCs. MPCs 
(myeloid progenitor cells) express CD34, CD33, and CD38, but GMPs express CD33, CD34, 
and CD31. Myeloblasts produce CD13, CD15, and CD33, whereas mature neutrophils 
produce CD17, CD32, CD35, CD43, and CD93.  These molecules are not expressed 
permanently but rather by inducers in environment. Inducible expression of CD molecules 
implies that a MC can survive no matter these molecules are expressed or not. If a mutation 
occurs to the gene of one of these molecules, the mutation may not affect the cell. Taken 
together, due to the anchor-independence for survival and the inducible expression of cell 
surface molecules, a MC and other blood cells may have higher survivability from DNA 
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changes than a tissue cell. Namely, a DNA change that is fatal for a tissue cell may not be 
necessarily fatal for a MC.  
7.2   A developing MC may have higher survivability from DNA changes than a mature 
MC 
A developing MC such as progenitor cell, myeloblast, and pro-cyte is immature on cell 
functions, thus it may be more tolerant to DNA changes than a mature MC. Having high 
integrity on cell functions, a mature cell is alert to any tiny change occurred to the cell. 
However, because of immaturity on some cell functions, an immature MC may be unable to 
“sense” a change in the cell.  In addition, to have full cellular functionality, a mature cell 
needs to express more types of molecules than an immature one. Thus, more genes should be 
activated in a mature cell. A DNA change that occurs to a gene that is activated only in 
mature cells can only affect a mature cell but not a developing cell. Namely, a DNA change 
that is fatal for a mature MC may be not fatal for an immature MC. Therefore, a developing 
MC may have higher tolerance to DNA changes than a mature cell.  The high survivability 
from DNA changes makes a developing MC have a risk to be transformed by a CC 
(chromosome change). 
However, a developing MC may have lower tolerance to DNA changes than a developing 
lymphoid cell (LC), such as lymphoblast and pro-lymphocyte. It is known that naïve 
lymphocyte is the smallest cell in our body.  A naïve lymphocyte has little cytoplasm, 
indicating that it does not produce many intracellular proteins. This means that most genes 
may be switched-off in a naïve lymphocyte and its precursor LCs. Differently, a mature MC 
such as monocyte and granulocyte has a large cytoplasm. This indicates that a 
monocyte/granulocyte produces a great deal of intracellular proteins.  It is probable that many 
genes that are not activated in a LC are activated in a MC.  Thus, a DNA change that has an 
effect on a MC may have no effect on a LC. Namely, a LC may be tolerant to more types and 
more number of DNA changes than a MC. Taken together, with respect to the tolerance to 
DNA changes, developing LC > developing MC > mature MC > tissue cell.  
VIII. A MC may require obtaining fewer cancerous properties for transformation 
than a tissue cell  
A tumor can grow rapidly and even invade into other organs due to some cancerous properties 
of the tumor cells (Cooper, 2000). Among all cancerous properties, the most important five 
are: stimulator-independent mitosis (SIM), loss of cell-contact inhibition (LCCI), production 
of matrix metalloproteinase (PMM), anoikis-resistance (AR), and acquired mobility (AM) 
(Table 2). SIM and LCCI are two essential properties for a non-malignant tumor cell. SIM 
gives a cell the ability of stimulator-independent proliferation. LCCI enables an unlimited cell 
proliferation by overcoming the cell-contact inhibition in a tissue. PMM, AR, and AM are 
essential properties for a malignant tumor cell. These three properties make a tumor cell 
invasive and metastatic. For a tissue cell, SIM and LCCI are the first two properties to acquire 
for cell transformation. Thus, transformation of a tissue cell often begins by non-malignant 
 Email : thomasjicun@gmail.com  18 
 
transformation. When a tumor cell acquires additionally one of PMM, AR, and AM, it 
undergoes malignant transformation (Wang-Michelitsch, 2018b).  
Interestingly, a blood cell and a HC are born with some properties similar to that of a cancer 
cell. Firstly, a blood cell is anoikis-resistant, thus it is AR-positive. Secondly, cell 
proliferation of HCs in marrow is not restricted by cell-contact inhibition; hence HCs are 
LCCI-positive. Thirdly, a blood cell has auto-mobility for migration in bloodstream, lymph, 
and tissues, thus it is AM-positive. Finally, a blood cell can produce matrix 
metalloproteinases during migration, thus it is PMM-positive. Taken together, a blood 
cell/HC is born with four properties that are needed for cell transformation, and these 
properties are LCCL, PMM, AR, and AM (Table 2). Hence, a blood cell/HC needs to obtain 
only “one” property: namely the SIM, for transformation. This means that a blood cell/HC 
can be transformed by fewer number of DNA changes than a tissue cell, thus it can be 
transformed more rapidly.  
 
Table 2. A blood cell may require obtaining fewer cancerous properties for transformation than a tissue cell  
Cancerous properties  Properties required to obtain for cell  transformation  
  Tissue cell Blood cell and  hematopoietic cell                                    
Stimulator-independent mitosis (SIM) For non-malignant 
transformation 
1 1 
Loss of cell-contact inhibition(LCCI) 1 0 
Production of matrix metalloproteinase (PMM) For further malignant 
transformation 
1 0 
Anoikis-resistance (AR) 1 0  
Acquired Mobility  (AM)  1 0 
 
 
IX. Our hypothesis: a MC may have two pathways on transformation: a slow and an 
accelerated  
Blood cancers including leukemia and lymphoma have high frequency of CCs in cancer cells. 
This indicates that CCs contribute to the cell transformations of MCs and LCs in blood 
cancers. As a type of blood cell, a MC may have higher survivability from DNA changes and 
require obtaining fewer cancerous properties for transformation than a tissue cell. On this 
basis, we hypothesize that a MC may have two pathways on transformation: a slow and an 
accelerated (Box 2).  Slow pathway is driven by accumulation of PDMs and MECCs through 
many generations of cells. Accelerated pathway is driven by accumulation of PDMs, MECCs, 
and IECC(s) through a few generations of cells. Transformations via different pathways occur 
at different ages. Thus, distinguishing between these two pathways of transformation of a MC 
can help us understand the age-specific incidences in AML, CML, and MDS. 
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Box 2. Hypothesis: a myeloid cell may have two pathways on cell transformation   
 
 
 
 
 
 
 
 
 
 
9.1   Slow pathway: by accumulation of PDMs and MECCs through many generations 
of cells 
A MC can be transformed when it acquires the property of stimulator-independent mitosis 
(SIM) by DNA changes. As discussed earlier, a normal MC including developing MC cannot 
survive from a GECC. Thus, a MC can acquire SIM only in two ways: by accumulation of 
PDMs/MECCs or by accumulation of PDMs/MECCs and IECC(s). A cell transformation 
driven by accumulation of PDMs/MECCs can occur to any one of MCs. In such a 
transformation, the last driver PDM/MECC is generated in the first transformed cell, but other 
driver PDMs/MECCs are generated in precursor HSCs/MCs but inherited by the transformed 
cell. Since HSCs are the unique long-living stem cells in marrow, long-term accumulation of 
PDMs/MECCs takes place mainly in HSCs. The accumulation of PDMs/MECCs in HSCs is a 
result of repeated cell injuries and repeated regenerations of HSCs. Accumulation of PDMs 
and MECCs is a slow process, because it needs to proceed through many generations of HSCs. 
Hence, the pathway of transformation by accumulation of PDMs/MECCs is a “slow pathway” 
(Figure 3).   
As a result of repetition of cell injuries, the incidence of cell transformation via this pathway 
increases with age. Thus, cell transformation via slow pathway takes place mainly at old age. 
A leukemia that results from cell transformation via slow pathway occurs mainly in adults and 
rarely in children. Thus, MDS may develop mainly via this pathway (Figure 4). Some adult 
subtypes of AML, such as M6, may develop via this pathway. CML occurs at any age; hence 
it may not develop via this pathway. 
 
 
 
 Slow pathway:  by accumulation of PDMs and MECCs through many generations of cells  
 Accelerated pathway: by accumulation of PDMs, MECCs, and IECC(s) through a few  generations of cells 
PDM: point DNA mutation                            
MECC: mild-effect chromosome change       
IECC: intermediate-effect chromosome change 
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Figure 3. Transformations of a MC via different pathways occur at different ages (a schematic graph) 
A MC may have two pathways on transformation: a slow (Black line) and an accelerated (Blue line). Slow 
pathway is driven by accumulation of PDMs and MECCs through many generations of cells. Accelerated 
pathway is driven by accumulation of PDMs, MECCs, and IECC(s) through a few generations of cells. 
Transformations via different pathways occur at different ages. A cell transformation via slow pathway occurs 
mainly in adults and has increasing incidence with age. A cell transformation via accelerated pathway can occur 
at any age and has also increasing incidence with age.  
 
9.2  Accelerated pathway: by accumulation of PDMs, MECCs, and IECC(s) through a 
few generations of cells 
A MC can obtain SIM also by accumulation of PDMs, MECCs, and IECC(s). Some forms of 
CCs in AML, such as t(9; 11), (+8), (-y), t(6;9),  t(9;22), (-5), (-7), inv (3), and abn(3q), may 
be IECCs. With stronger effect than a PDM/MECC, an IECC can accelerate cell 
transformation driven by accumulation of PDMs/MECCs. Thus, a cell transformation driven 
by IECC(s) and PDMs/MECCs is rapider than that driven only by PDMs/MECCs in slow 
pathway. We refer the IECC-driven pathway as to an “accelerated pathway” (Figure 3). A 
transformation via accelerated pathway needs to be achieved also through some generations 
of cells, but fewer than that in slow pathway. An IECC can be generated in a cell at any time; 
however it may have increasing occurrence in MCs with age of our body. Therefore, a cell 
transformation via accelerated pathway can occur at any age, but it has increasing incidence 
with age. A leukemia that develops via this pathway occurs in both adults and children, but 
more in adults. Thus, CML develops more likely via this pathway, and Ph translocation is the 
IECC in CML (Figure 4). Pediatric AMLs and some adult AMLs, such as M1, M2, M3, M4, 
and M5, may develop via this pathway. 
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Figure  4. The age of occurrence of leukemia is determined by the transforming pathway of a MC  
A MC may have two pathways on cell transformation: a slow pathway by accumulation of PDMs and MECCs 
through many generations of cells, and an accelerated pathway by accumulation of PDMs, MECCs, and IECC(s) 
through a few generations of cells. In these two pathways, the final PDM/MECC/IECC is generated in the first 
transformed cell, but other PDMs/MECCs/IECC(s) are generated in precursor HSCs/MCs. Transformations via 
different pathways occur at different ages. Thus, the age of occurrence of leukemia is determined by the 
transforming pathway of a MC. A leukemia that occurs mainly in adults, such as MDS and adult AML, is often a 
result of cell transformation via slow pathway. A leukemia that occurs in both children and adults, such as CML 
and pediatric AML, is more likely a result of cell transformation via accelerated pathway.    
 
Similar to that in slow pathway, most of the driver PDMs/MECCs in a cell transformation via 
accelerated pathway are generated in the precursor HSCs/MCs of the first transformed cell. 
Thus, cell injuries of HSCs in marrow may contribute to developments of all forms of 
myeloid leukemia, including AML, CML, and MDS. Since HSCs have low tolerance to an 
IECC, the IECC associated with development of AML/CML may be more often generated in 
the first transformed MC or one of its precursor MCs.  
X. Three grades of transformation of a MC: low, high, and intermediate  
MC: myeloid cell 
MDS: myelodysplastic syndrome 
MECC: mild-effect chromosomal change 
PDM: point DNA mutation 
 
 
AML: acute myeloid leukemia 
CML: chronic myeloid leukemia 
GECC: great-effect chromosomal change  
HSC: hematopoietic stem cell 
IECC: Intermediate-effect chromosomal change 
  
 
 
A final PDM/MECC/IECC in a MC 
Cell transformation at ANY age, with 
INCREASING incidence with age 
Accelerated pathway 
CML and pediatric AML  
Accumulation of PDMs/MECCs/IECC(s) in 
HSCs and precursor MCs 
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Leukemia is a fatal disease, because accumulation of leukemia cells in marrow cavity can 
cause failure of hematopoiesis. Failure of cell differentiation of leukemia cells is the main 
reason for the accumulation of leukemia cells in marrow cavity. Thus, the severity of 
leukemia is determined mainly by the degree of cell differentiation of leukemia cells. If the 
cell differentiation is normal, leukemia cells can develop into mature cells, which can enter 
bloodstream and do not accumulate in marrow.  However, if the cell differentiation is 
abnormal, leukemia cells cannot develop into mature cells and have to accumulate in marrow.  
Thus, the cell transformations of a MC in different forms of leukemia may be different by 
“grades”. Transformation of a cell can be differentiation-affected or differentiation-non-
affected. If cell differentiation is not at all affected, the transformation is at low-grade. If cell 
differentiation is severely affected, the transformation is at high-grade.  There is still a third 
situation: if cell differentiation is partially affected, the transformation is at intermediate-
grade. Thus, a cell may have three grades of transformation: low-grade, high-grade, and 
intermediate-grade. A tissue cell is often transformed firstly at low-grade then high-grade. 
However, for a MC, the situation is different. A developing MC can be transformed directly at 
all three grades, but a mature MC needs to be transformed firstly at low-grade. 
In a cancer developed from a tissue cell, the grade of transformation determines whether the 
cancer is non-malignant (low-grade) or malignant (intermediate-grade or high-grade). 
However, for a MC, transformations at different grades will lead to different forms of 
leukemia. For example, low-grade transformation of a MPC may result in CML development; 
however transformation of a MPC at intermediate-grade or high-grade may result in MDS 
development (Table 3). Low-grade transformation of a developing MC may result in MPN 
development; however transformation of a developing MC at intermediate-grade or high-
grade may result in AML development. In both of slow and accelerated pathways, the cell 
transformation of a MC can be firstly at low grade, leading to occurrence of a proliferative 
disease such as CML and MPN. However, when one of the leukemia cells in CML/MPN is 
transformed further at intermediate-grade or high-grade, MDS/AML may occur. Low-grade 
transformation of a HSC may result in occurrence of clonal hematopoiesis. 
 
Table 3. The grades of cell transformation of a MC in AML, CML, MDS, and MPN  
Cell of origin Low-grade cell transformation  Intermediate-grade or high-grade  cell transformation 
HSC Clonal hematopoiesis  MDS? 
MPC CML  MDS 
Developing MC MPN  AML 
 
XI. Developments of pediatric AML and CML may be associated with the repeated 
bone-remodeling during bone-growth 
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Our analysis shows that pediatric AML/CML may be a result of transformation of a MC via 
accelerated pathway. In this part, we will interpret the developing characters of AML, CML, 
and MDS by our hypothesis. Firstly, although these three forms of leukemia are different by 
occurring age, pathology, and prognosis, they may have common causes. They may be all 
related to the cell injuries of HSCs and MCs caused by external and/or internal damaging 
factors. For adult cases, repeated exposures to radiation/chemicals and repeated bone-
remodeling during bone-growth and bone-repair may be all related to leukemia development. 
However, for pediatric cases, repeated bone-remodeling during bone-growth may be a more 
important causing factor. On all three forms of myeloid leukemia, men have higher incidences 
than women. One reason may be that: men have higher risk of bone injuries by their heavier 
body weight and heavier physical work.  
11.1 AML: as a result of high-grade transformation of a developing MC via slow or 
accelerated pathway 
AML can occur at any age and has increasing incidence with age. Thus, AML may develop as 
a result of cell transformation of a MC via slow or accelerated pathway. AML has two times 
of incidence as CML. The higher incidence of AML than CML may be due to two factors: A. 
AML can develop from all types of developing MCs, but CML arises only from a MPC; and 
B. AML can develop via both slow and accelerated pathways, but CML develops mainly via 
accelerated pathway. Pediatric AML develops more likely via accelerated pathway, whereas 
adult AML may develop via slow or accelerated pathway (Table 4). Among all the CCs in 
AMLs, some forms including t(6; 9),  (–5), inv (3), t(9;22), and abn(3q) may be IECCs, 
because they are associated with a poor prognosis of AML.  The AMLs that have these IECCs 
may develop via accelerated pathway. Other forms including t(15; 17), t(8; 21), inv(16), 
t(11;17), and t(9;11) may be MECCs, because they are related to a good prognosis of AML.  
The severity of an AML is determined by two factors: the maturity of the cell-of-origin and 
the grade of cell transformation. For a developing MC, high-grade transformation will lead to 
failure of cell differentiation and production of immature leukemia cells; low-grade 
transformation will lead to over-production of mature cells; and intermediate-grade 
transformation may result in insufficient production of mature cells. The hematopoiesis is 
affected in all subtypes of AML, suggesting that the cell transformations of MCs in AMLs are 
all at high-grade or intermediate-grade. Among all subtypes, M3, M4, and M5 have better 
prognoses than others, suggesting that the leukemia cells in these subtypes can produce 
mature cells. Thus, the cell transformations in M3, M4, and M5 may be all at intermediate-
grade. Similarly, in M1 and M2, the leukemia cells have minimal or partial maturation, 
suggesting that M1 and M2 may be results of intermediate-grade cell transformations of MCs.    
On this basis, we make a prediction for the cell of origin and the grade of cell transformation 
in each subtype of AML: M0: by high-grade transformation of a myeloblast; M1 and M2: by 
intermediate-grade transformation of a myeloblast; M3: by intermediate-grade transformation 
of a pro-myelocyte; M4 and M4eos: by intermediate-grade  transformation of a GMP 
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(Granulocyte-Monocyte Progenitor); M5: by intermediate-grade transformation of a pro-
monocyte; M6: by high-grade or intermediate-grade transformation of an erythroblast or a 
pro-erythrocyte; and M7: by high-grade or intermediate-grade transformation of a 
megakaryoblast or a pro-megakaryocyte. Although AML develops by high-grade or 
intermediate-grade transformation of a developing MC, it may begin sometimes by low-grade 
transformation, which may appear as an asymptomatic MPN. 
 
Table 4. Pathways of cell transformation of a MC in AML, CML, and MDS  
 Driver DNA changes Cell of origin Pathway of 
transformation 
Grade of 
transformation 
Pediatric AMLs and 
some adult AMLs 
Accumulation of 
PDMs/MECCs/IECC(s)   
Developing MC Accelerated High or intermediate 
Adult subtype of 
AML 
Accumulation of PDMs/MECCs   Developing MC Slow High or intermediate 
CML Accumulation of PDMs/MECCs +    
Ph translocation  
MPC  Accelerated Low 
MDS Accumulation of PDMs/MECCs   MPC/HSC? Slow High or intermediate 
 
11.2 CML: as a result of low-grade transformation of a myeloid progenitor cell (MPC) 
via accelerated pathway 
In CML, all the lineages of MCs are affected, thus CML originates more likely from a MPC 
(Table 4). Since HSCs have low survivability from an IECC, the Ph translocation in CML 
may be generated in a MPC. MPCs can regenerate for some generations. Ph translocation is 
found in 95% of CMLs but only in 5% of AMLs. This suggests that a MPC may have higher 
tolerance to Ph translocation than other developing MCs. However, Ph translocation is the 
main form of CC in CML-CP, indicating that a MPC may have low survivability from a CC 
except Ph translocation. In another word, apart from Ph translocation, a MPC can be 
transformed mainly by accumulation of PDMs/MECCs.  
CML is a proliferative disease, suggesting that it is a result of low-grade transformation of a 
MPC (Table 3). The progression of CML from chronic phase to blast crisis may be a result of 
cell transformation of a MPC from low-grade to high-grade.  The CCs observed in CML, 
including t(8;21), second Ph translocation, iso(17q), and (+19), may be secondary DNA 
changes. However, some of them may drive further transformation of CML cells. Ph 
translocation may be related to the generation of some of the secondary DNA changes.  As a 
form of CC, Ph translocation may affect the genomic stability in a cell and make a CML cell 
more fragile to DNA damage (Neviani, 2014). 
 Email : thomasjicun@gmail.com 25 
 
CML is a form of MPN. However, CML can occur at all ages but other types of MPNs such 
as ET and PV occur only in adults. Other types of MPNs do not have Ph translocation in 
tumor cells. This suggests that Ph translocation is an accelerating factor in CML development. 
Namely, it is the Ph translocation that is responsible for the occurrence of CML in a child. 
TKIs are effective drugs in controlling CML. However, TKIs can only inhibit cell 
proliferation but cannot kill leukemia cells. Thus, for a CML patient, TKIs need to be given 
for a long period of time, and this is very expensive. 
11.3   MDS: probably as a result of high-grade transformation of a MPC via slow 
pathway  
Occurring mainly in old people, MDS develops more likely via slow-pathway of cell 
transformation (Table 4) (Harada, 2015). MDS originates more likely from a MPC. The 
reason is that: in MDS, the hematopoiesis of all the myeloid lineages is affected, but that of 
lymphoid lineage is not affected. The defective hematopoiesis in MDS should be a 
consequence of failure of cell differentiation of the leukemia cells. This indicates that MDS 
develops by high-grade or intermediate-grade transformation of a MPC. Ph translocation is 
the main form of CC in CML-CP. This indicates that a MPC may have low tolerance to a CC 
except Ph translocation. Hence, the cell transformation of a MPC in MDS development is 
driven mainly by accumulation of PDMs/MECCs. MDS may begin by low-grade cell 
transformation of a HSC/MPC, which appears as clonal hematopoiesis. Studies show that 
some MDS-associated gene mutations can be found in blood cells in 5% of healthy old people 
(Harada, 2015). These people may have clonal hematopoiesis indeterminate potential (CHIP). 
CHIP may proceed into MDS when an offspring MPC of the clonal HSCs undergoes 
intermediate-grade or high-grade transformation. Although forms of CCs are observed in 
MDS cells, including del(5q), del(7q), del(20q), (-5), and (-7), they may be mostly secondary 
DNA changes.  
MDS and secondary AML are often treatment-resistant. Two factors may be associated with 
the treatment-resistance of an adult cancer (leukemia): the heterogeneity of cancer cells and 
the existence of pre-cancer cells. Firstly, cancer heterogeneity is a result of generations of 
secondary DNA changes in cancer cells. During the slow progression of an adult cancer, 
different secondary DNA changes may be generated in different cells. Thus, different cancer 
cells will have different sensitivities to a treatment. Secondly, in an adult cancer, the “sister 
cell” and some of “cousin cells” of the first transformed cell are s kind of “pre-cancer cells”. 
These cells have most of the DNA changes that the transformed cell has, because they all 
have the same precursor HSCs and MCs. A pre-cancer cell can be promoted to transform by 
chemotherapy or radiotherapy (Rothkamm 2002). Thus, existence of pre-cancer cells may be 
a reason for the relapse of an adult cancer (leukemia). In targeted treatment, the selected target 
DNA changes should be those that are generated earlier, because these DNA changes may 
exist in all tumor cells. However, further progression of a cancer may anyway alter the 
sensitivities of cancer cells to a treatment. Targeted treatment may be beneficial for some 
patients, but its effect is limited. 
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11.4   Infant AML and JMML: are they consequences of defective development of MCs? 
AML has a small peak incidence before age 2. In our view, only a cell transformation via 
rapid pathway can have a peak incidence at certain age (Wang-Michelitsch, 2018b). Thus, we 
hypothesize that some Infant AMLs (IAMLs) may develop by rapid cell transformation of an 
abnormal-developed MC by a great-effect CC (GECC). In our recent discussions on lymphoid 
leukemia, we have proposed that a developing lymphoid cell such as lymphoblast may have a 
risk to be transformed by a GECC. We found out that, by the hypothesis of a rapid pathway of 
transformation of a lymphoblast, we can understand the big peak incidence of ALL in 
children (Wang-Michelitsch, 2018b). However, a normal developing MC may be not tolerant 
to a GECC and unable to be transformed via rapid pathway. In addition, ALL peaks at age 2-5, 
but IAML peaks at age 0-2. The peak of IAML is much smaller than that of ALL. These 
differences between ALL and IAML indicate that IAML may have a distinct causing factor 
from pediatric ALL. 
It is known that IAML children have often hereditary conditions, including Down syndrome, 
Fanconi anemia, Diamond-Blackfan syndrome, and Li-Fraumeni syndrome (Saida, 2017). A 
child with Down syndrome has 16-fold risk higher than other children on IAML development. 
It is possible that infants of these syndromes have deficiencies on functions of HSCs/MCs due 
to congenital genetic abnormalities. A genetic abnormality may have two effects on a MC: 
defective cell differentiation and reduced genome stability. On one hand, the defective cell 
differentiation can make a MC have increased tolerance to DNA changes. On the other hand, 
forms of CCs such as t(1;22) and MLL rearrangements can be generated in a MC as a 
consequence of genome instability. As a co-effect, a poor-developed MC may be able to 
survive from a GECC and even be transformed by the GECC. Complex karyotypes are 
GECCs, and they are often seen in IAML cells. This may prove that IAML cells can survive 
from a GECC. Similarly, some MLL rearrangements and t(1;22) may be also GECCs, because 
they are mostly seen in IAMLs. Taken together, we hypothesize that IAML may develop as a 
consequence of defective development of HSCs/MCs by a genetic disorder.  
JMML may develop also as a result of rapid cell transformation of a poor-developed MC. The 
cell of origin of JMML may be a granulocyte-monocyte progenitor (GMP). Some forms of 
abnormalities on chromosome 7, such as (+7) and (-7), may be the GECCs that are 
responsible for the “one-step” transformation of a GMP in JMML. The cell transformation in 
JMML may be at intermediate-grade, because the leukemia cells in JMML are relatively 
mature and they can enter bloodstream and infuse into organs. 
XII.  Summary  
We have discussed in this paper the causing factors and the mechanism of cell transformation 
of a MC in development of myeloid leukemia. Here we give an outline of our work on 
studying AML and CML (Figure 5).  
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Figure 5.  Our understanding of the pathogenesis of myeloid leukemia  
This is an outline of our work on studying the pathogenesis of myeloid leukemia. DNA changes are triggers for 
cell transformation. DNA changes are generated in cells as consequences of cell injuries and DNA injuries.  In 
our view, repeated bone-remodeling during bone-growth is a potential source of cell injuries of HSCs/MCs in 
marrow cavity. Generation and accumulation of DNA changes in HSCs/MCs are results of repeated cell injuries 
and repeated cell proliferation. 
DNA changes have four types by their effects on a cell: PDM, MECC, IECC, and GECC.  Different types of DNA 
changes may drive cell transformations of a MC at different grades (low, high, or intermediate) and via 
different pathways (slow or accelerated). The form or subtype of AML/CML is determined by the grade of cell 
transformation of a MC. The age of occurrence of AML/CML is determined by the transforming pathway of a 
MC. The underlined parts in blue color in the figure are our work.  
 
XIII. Conclusions  
We have discussed in this paper the causes and the mechanism of transformation of a MC. We 
raise two hypotheses based on our discussion. Hypothesis A is: repeated bone-remodeling 
during bone-growth and bone-repair may be a source of cell injuries of marrow cells 
including HSCs, MCs, and LCs. Hypothesis B is: a MC may have two pathways on 
transformation: a slow and an accelerated. A transformation via slow pathway occurs at old 
age; whereas that via accelerated pathway occurs at any age. Therefore, CML and pediatric 
AML may develop as a result of transformation of a developing MC via accelerated pathway. 
Repeated bone-remodeling during bone-growth and bone-repair   + external damage 
 
Cell injuries and DNA injuries of HSCs/MCs in marrow 
 
Generation and accumulation of DNA changes in HSCs/MCs 
 
Different types of DNA changes by effects on a cell (PDM, MECC, IECC, and GECC) 
Development of AML /CML 
Cell transformation of a MC  
Causes for generation 
of DNA changes in MCs 
Cell transformation of 
a MC by DNA changes  
Form or subtype 
of AML/CML  
Occurring age 
of AML/CML  
Two pathways of transformation 
(slow and accelerated)    
Three grades of cell transformation 
(low, high, and intermediate) 
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MDS and adult AML may develop as a result of transformation of a developing MC via slow 
pathway. Thus, distinguishing between the two pathways of transformation of a MC can help 
us to understand why AML, CML, and MDS occur at different ages.  
To verify our hypothesis that bone-remodeling is related to the developments of AML and 
CML, experimental researches can be undertaken to study the association of repeated bone 
injuries with the incidence of myeloid leukemia in animal models (such as rabbits). 
Occurrence of leukemia in a child is a tragedy. Our discussion can make us better understand 
this tragedy. Pediatric AML/CML may develop as a co-effect of three factors: A. higher 
survivability of a MC from DNA changes than a tissue cell; B. requiring obtaining fewer 
cancerous properties of a MC for cell transformation than a tissue cell, and C. higher risk of 
cell injuries of HSCs/ MCs in a child by repeated bone-remodeling for bone-growth. Thus, for 
reducing the risk of occurrence of AML/CML, avoiding violent sports and bone-injuries may 
be helpful. Cryopreservation of the HSCs in umbilical cord at birth is advised for the entire 
population.  
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